Full-Time

Clinical Study Manager 3

Posted on 11/12/2025

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Google Cloud Platform
Requirements
  • Previous experience implementing, supporting and managing medical device trials
  • Significant knowledge of clinical and/or outcomes research study design
  • Strong experience in protocol and Informed Consent Form development, writing clinical section(s) for regulatory submission
  • Strong experience in conducting literature searches, reviews and appraisal of the scientific data
  • Excellent ability to interact with physicians and other professionals inside and outside the company
  • Knowledge of Good Clinical Practice ICH/GCP and other applicable regulations, fundamental understanding of clinical research and monitoring requirements
  • Experience negotiating clinical research contracts and budgets
  • Must be able to work effectively on cross-functional teams
  • Must be able to travel 25-40% or depending on business requirements
  • Must be able to manage multiple projects and/or balance competing priorities
  • Strong communication, presentation and interpersonal skills with high attention to detail and organization
  • Ability to learn quickly, adapt to shifting requirements, and self-educate on different surgical specialties as applicable to clinical projects ("Self-starter attitude")
  • Ability to lead project team consisting of CRAs and CTAs and support management with relevant study updates
  • Exhibits strong work ethic to help meet aggressive timelines or multiple projects when necessary with a problem-solving mindset
  • Advanced degree in a scientific/bioengineering field (M.S., Ph.D. or M.D.) with a minimum of 3-4 years of experience in clinical research, or Bachelor’s degree in a scientific/bioengineering field with a minimum of 5 years of experience in clinical research is preferred
Responsibilities
  • Lead assigned clinical research activities
  • Collaborate with internal stakeholders, investigators and Key Opinion Leaders to develop and review study design and concepts, prepare protocol and study outlines and subsequently driving identified initiatives
  • Plan and execute the clinical studies including site selection, analysis of potential patient recruitment and projections, creation of study related documents (protocols, case report forms, Informed consents, Clinical trial agreements, study reports), organizing Institutional Review Board and Ethics Committee submissions with follow-through to ensure successful progress
  • Independently conduct clinical studies on schedule and within budget while ensuring high quality and compliance
  • Perform on-site and remote site qualification visits, site initiation visits, interim monitoring visits and site close out visits
  • Conduct clinical study monitoring to ensure regulatory and protocol compliance as well as overall data accuracy in accordance with the study clinical monitoring plan
  • Complete source data verification of clinical study data entered in an Electronic Data Capture system or on a case report form at sites or in data listings to ensure regulatory and protocol compliance and overall accuracy
  • Liaise with sites and support in internal audit/inspection and ensure sponsor audit readiness
  • Liaise with external vendors and sites to negotiate contracts and budgets in collaboration with the legal team and management
  • Track study progress and provide regular status reports
  • Work closely with Biostatisticians on data analysis, interpretation and synthesis, in order to develop clinical study reports and/or support development of scientific publications
  • Track, process and manage site payments and support in study financial tracking by developing tracking tools as necessary
  • Organize and lead study meetings and other study activities as assigned
  • Mentor junior clinical study manager(s); provide guidance to CRAs and CTAs on monitoring and other study needs
  • Follow corporate SOPs and regulatory requirements including GCP and US and international guidelines and proactively manage studies
  • Conduct literature searches and familiarize with literature to stay informed and abreast of relevant scientific/clinical knowledge and/or to determine evidence gaps
  • Critically appraise scientific literature and write clinical summaries to assist research and the development of clinical strategies and clinical investigational protocols
  • Review and revise Clinical Operations SOPs to assist Clinical Affairs leadership with continuous process improvement initiatives
  • For post-market research, collaborate with commercial groups to understand market trends and utilize information to support business goals through Clinical Affairs activities
  • For post-market research, provide scientific expertise to Health Economics and Outcomes Research department for development of outcomes research analysis
  • Work with clinical investigators to prepare manuscripts, abstracts, slide presentations, and poster presentations for scientific meetings and publications in collaboration with management
  • Support regulatory submission and approval of pre-market clinical studies and 510(k)s, responsible for addressing regulatory body questions on clinical study design and results
Desired Qualifications
  • Comfortable in a hospital environment, experience working with nurses and surgeons preferred
  • Understanding of statistics, statistical methods, and design of experiments is strongly preferred

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • da Vinci 5 updates create software-driven upgrades and workflow monetization.
  • Ion growth expands a second engine beyond soft-tissue robotic surgery.
  • Installed base above 11,000 systems supports durable consumables and service growth.

What critics are saying

  • FDA recalls on da Vinci instruments threaten recurring revenue and surgeon trust.
  • Lower-cost robotic rivals pressure placements, pricing, and hospital contract renewals.
  • MedTech valuation compression can outpace Intuitive's earnings growth for months.

What makes Intuitive Surgical unique

  • Pioneer of robotic-assisted surgery, anchored by da Vinci and Ion platforms.
  • Global leader in minimally invasive care, serving hospitals and surgical centers.
  • Large recurring revenue base from instruments, accessories, and service contracts.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Intuitive Surgical who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.

INACTIVE